Senior Research Scientist at IBA with over 20 years of experience in product development in multinational companies. I graduated at the university of Liège in Belgium with a PhD in physical chemistry. I now work in the research group at IBA and I have a special interest for FLASH proton therapy. I manage different research collaborations in medical technology between IBA, universities and research institutions. I also act as a community co-manager of the open source software platform for proton therapy: https://openpath.software/

Head of Department of Oncology, Canarian Comprehensive Cancer Center, San Roque University Hospital, Las Palmas, Director, Canarian Comprehensive Cancer Center, San Roque University Hospital, Las Palmas Full Professor and Chair of Oncology, Fernando Pessoa Canarias University Director PhD, Postgraduata and Research School Fernando Pessoa Canarias University Director Canarian Institute for Cáncer Research Member Clinical Committee of the European Society of Radiotherapy and Oncology ESTRO Member National Societies Committee of the European Society of Radiotherapy and Oncology ESTRO President Radiation Oncology National Commission, Spanish Government Ministry of Health President Radiotherapy & Radiation Oncology Section European Union of Medical Specialties

I graduated from Villanova University in 2020 with a B.S. in biochemistry. Since then, I have worked as a research assistant at Vanderbilt University Medical Center in the Department of Radiation Oncology under Dr. John Eley.

I am a postdoctoral researcher in the laboratory of Dr. Marie-Catherine Vozenin at the CHUV in Lausanne, Switzerland, where I have the opportunity to work on cutting-edge FLASH radiotherapy (RT). In 2020 I earned a Ph.D. in Environmental Health Sciences at the University of California, Irvine (UCI) under Dr. Charles Limoli, having studied the mitigation of RT-associated cognitive dysfunction using extracellular vesicles (EV) derived from neural stem cells and the mechanism involved. The work in the Limoli lab combined my interest in epigenetics and the “nature vs. nurture” question with the subject of environmental toxicology and growing importance of the issue of how environmental exposures affect health and disease. A question with ever more importance as the world becomes more interconnected and the incidence of cancer rising. It is imperative that the treatment of diseases like cancer do not leave patients so burdened that they are unable to enjoy life after treatment. A common thread throughout both my doctoral and postdoctoral work has been the mitigation of normal tissue damage surrounding RT.

With more than 25 years working in the medical device industry, Philippe has led several projects in leading companies and developed innovative products. From radiotherapy dosimetry, X-ray tube engineering, image acquisition and treatment, integration & validation, electron beam sterilization and linac engineering, Philippe’s diverse skills are essential to the projects’ development. Now Radiotherapy Product Manager at THERYQ, he leads multi-disciplinary teams to develop FLASHKNiFE and other future products.

Tristan is currently a fourth year medical student at the University of Pennsylvania, who is currently applying for internal medicine residencies this fall with plans to pursue a subsequent hematology/oncology fellowship. He is interested in exploring a translational research career that utilizes bioinformatics to advance efforts in precision medicine.

One of the main goals of my research program is to advance FLASH radiotherapy from the bench to the clinic. To this end, we have been successful in obtaining NCI funding for a program project grant aimed to characterize this novel irradiation modality that challenges some of the most fundamental tenets in radiobiology. FLASH radiotherapy is able to achieve remarkable improvements in therapeutic gain through ultrahigh dose rate (≥ 100 Gy/s) delivery. My team that includes Marie-Catherine Vozenin at the CHUV in Switzerland, Bill Loo at Stanford University, Peter Maxim at Indiana University and Doug Spitz at the University of Iowa have generated data in support of several mechanisms, of which one involves a mechanism that minimizes radiation-induced oxygen toxicity and exploits the differential redox biology between tumors and normal tissue. While tumor cure is iso-efficient between FLASH and conventional dose rate modalities, FLASH induces transient and radioprotective hypoxia that affords significant sparing of normal tissue injury in the brain (and throughout all other organs analyzed). Collectively, my research strives to generate the requisite data necessary to facilitate the rapid implementation of this innovative irradiation platform, using both electron and X-ray beams, into the clinic.

Billy W. Loo, Jr., M.D., Ph.D. is a Professor of Radiation Oncology, a member of the Molecular Imaging Program at Stanford (MIPS) in the Department of Radiology, and a member of the Stanford Cancer Institute, in the School of Medicine. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program at Stanford. His clinical specialties are state-of-the-art radiation therapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR) and 4-D image-guided radiation therapy for lung tumors. Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member, chair, or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, including the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR), and American Society of Radiation Oncology (ASTRO). His clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. As part of this work, he leads a clinical and preclinical research program in molecular imaging, particularly using novel PET tracers for tumor hypoxia (EF5), tumor proliferation (FLT), and neuroinflammation (PBR06). He also co-leads clinical trials of novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias. Since conceiving of a fundamentally new approach to delivering ultra-rapid, ultra-precise radiation therapy, pluridirectional high-energy agile scanning electronic radiotherapy (PHASER), Dr. Loo's major laboratory research focus has been to co-lead a collaborative effort between the Stanford Cancer Institute and SLAC National Accelerator Laboratory to develop PHASER into a transformative yet clinically practical technology. This program comprises both technology development and fundamental research on the radiobiology of extremely rapid FLASH radiation therapy to optimize the biological therapeutic index. Dr. Loo received his MD from University of California, Davis and his PhD in Bioengineering from University of California, San Francisco and Berkeley. He completed his Radiation Oncology residency training at Stanford University. He is certified by the American Board of Radiology in Radiation Oncology.

João Lourenço started his PhD in February 2021, investigating a novel strategy for delivering FLASH radiotherapy with multi-beams. He finished his MSc. in Engineering Physics from Instituto Superior Técnico in 2019, with a thesis with the title "Neutronic studies of an irradiation facility coupled to a proton cyclotron". From Nov. 2019 to Nov. 2020 he also received a research grant for conducting a feasibility study for a neutron irradiation facility coupled to a 250 MeV cyclotron intended for proton therapy.

I am a second year DPhil student at the University of Oxford, with my background including a masters degree in Mathematics & Physics (The University of Manchester, 2020) and a masters degree in Radiation Biology (University of Oxford, 2021). The main focus of my project is the clinical implementation of FLASH radiotherapy and in particular the implementation of ultra-high dose rate protons.

Hui Luo, radiation oncology, PHD in Zhengzhou University from 2016.9-2020.6, and Postdoc in CHUV/UNIL from 2021.9-2022.9. In the periord of Postdoc, I studied FLASH radiotherapy under the guidance of professor Marie Catherine Vozenin. My work is about endoplasmic reticulum stress and FLASH effect.